登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)
IBI363 (PD-1/IL-2α-bias) in Combination With Chemotherapy as Neoadjuvant Therapy in Initially Unresectable Stage III Non-Small Cell Lung Cancer
ClinicalTrials.gov 上登记的一项肺癌开放试验,由上海市肺科医院牵头,本站收录的另外 0 家医院列为研究中心。
状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月18日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。
研究团队的联系方式见登记记录。本站不转递咨询。
列出这项试验的中国大陆医院 1
登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。
登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心
来源:ClinicalTrials.gov 登记记录 NCT07408635,读取于 2026年11月18日;医院名称与本站医院名单匹配。 名称如何匹配
这项试验的核对清单 7
只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。
展开清单(7 项)收起清单
18 岁 至 未注明;性别:不限
登记记录的入选字段
Tumours with mixed NSCLC histology must be categorised as either squamous or non-squamous on the basis of the predominant component. Tumours containing both NSCLC and small-cell lung cancer (SCLC) are excluded.
入选标准第 5 条
Fertile female patients must voluntarily use effective contraception during the study period and for at least 3 months after treatment completion, and urine or serum pregnancy test result within 72 hours prior to enrollment are negative and must not be breastfeeding. Male patients with female partners of childbearing potential must use effective contraception during the trial and for 3 months after the last dose of IBI363.
入选标准第 18 条
Participants who were systemically treated with corticosteroids (prednisone or other corticosteroids >10 mg/ day) or other immunosuppressive agents within 2 weeks prior to first administration. In the absence of active autoimmune disease, inhaled or topical corticosteroids and adrenal hormone replacement therapy are permitted.
排除标准第 11 条
Eastern Cooperative Oncology Group (ECOG) performance status 0-1.
入选标准第 3 条
ANC count ≥ 1.5 × 10⁹/L
入选标准第 9 条
Platelet count ≥ 100 × 10⁹/L
入选标准第 10 条
Hemoglobin ≥ 90 g/L
入选标准第 11 条
Serum Cr ≤ 1.5 times of upper limit of normal (ULN) or calculated creatinine clearance (CLcr) ≥ 50 mL/min
入选标准第 12 条
Total bilirubin ≤ 1.5 × ULN (≤ 3 × ULN in Gilbert's syndrome)
入选标准第 13 条
AST and ALT ≤ 2.5 × ULN
入选标准第 14 条
INR or APPT ≤ 1.5 × ULN
入选标准第 15 条
At least one measurable lesion per RECIST v1.1.
入选标准第 7 条
Histologically confirmed the presence of small cell lung cancer component.
排除标准第 3 条
The subject has congenital or acquired immune deficiency (such as HIV infected persons).
排除标准第 15 条
勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:分期或严重程度(按试验的定义);怀孕、哺乳与避孕。
按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT07408635,读取于 2026年11月10日。
登记的入选标准
依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。
入选标准:Inclusion Criteria:
The patient shall sign the informed consent. Age ≥ 18 years. Eastern Cooperative Oncology Group (ECOG) performance status 0-1. Histologically or cytologically confirmed Stage III (per AJCC 9th) squamous or non-squamous non-small-cell lung cancer (NSCLC) deemed unresectable by the investigator. Tumours with mixed NSCLC histology must be categorised as either squamous or non-squamous on the basis of the predominant component. Tumours containing both NSCLC and small-cell lung cancer (SCLC) are excluded. "Unresectable" is defined as following: (1) Multistation or confluent metastasis in ipsilateral mediastinal lymph nodes (2)Contralateral or supraclavicular lymph node metastasis (N3) (3)Invasion of critical organs or major blood vessels (4)Extensive invasion of the chest wall and pleura (5)Special anatomical locations (6)Patient intolerance to lobectomy or pneumonectomy. At least one measurable lesion per RECIST v1.1. Adequate organ function meet the following standards (within 14 days before first dose, any blood components or growth factor drugs is not permitted): ANC count ≥ 1.5 × 10⁹/L Platelet count ≥ 100 × 10⁹/L Hemoglobin ≥ 90 g/L Serum Cr ≤ 1.5 times of upper limit of normal (ULN) or calculated creatinine clearance (CLcr) ≥ 50 mL/min Total bilirubin ≤ 1.5 × ULN (≤ 3 × ULN in Gilbert's syndrome) AST and ALT ≤ 2.5 × ULN INR or APPT ≤ 1.5 × ULN left ventricular ejection fraction (LVEF) ≥ 50 % Contraception and reproductive status: Fertile female patients must voluntarily use effective contraception during the study period and for at least 3 months after treatment completion, and urine or serum pregnancy test result within 72 hours prior to enrollment are negative and must not be breastfeeding. Male patients with female partners of childbearing potential must use effective contraception during the trial and for 3 months after the last dose of IBI363.排除标准:Exclusion Criteria:
Non-squamous and squamous NSCLC with EGFR active mutation positive, ALK rearrangement, or any other driver mutation with an approved targeted therapy. History of other malignant tumors within five years or concurrently present, except adequately treated cervical carcinoma in situ, basal- or squamous-cell skin carcinoma, localized prostate cancer after radical prostatectomy, ductal carcinoma in situ after radical prostatectomy, or other tumor deemed cured by the investigator. Histologically confirmed the presence of small cell lung cancer component. Participants who have received any systemic anti-cancer treatment. Clinically significant cardiovascular or cerebrovascular disease, including: Myocardial infarction or unstable angina within 6 months before first dose Stroke or transient ischaemic attack within 6 months before first dose Uncontrolled hypertension (systolic ≥ 160 mmHg and/or diastolic ≥ 100 mmHg) despite optimal therapy Congestive heart failure (NYHA class III-IV) Myocarditis Participants who were systemically treated with corticosteroids (prednisone or other corticosteroids >10 mg/ day) or other immunosuppressive agents within 2 weeks prior to first administration. In the absence of active autoimmune disease, inhaled or topical corticosteroids and adrenal hormone replacement therapy are permitted. Presence of any active autoimmune disease or history of autoimmune disease. Idiopathic pulmonary fibrosis, organizing pneumonia, drug pneumonia, or active pneumonia shown on CT during screening period have been or are currently present. History of allogeneic haematopoietic stem-cell or solid-organ transplantation. The subject has congenital or acquired immune deficiency (such as HIV infected persons). Active hepatitis (HBsAg positive and HBV DNA >the upper limit of normal value; HCV antibody and HCV RNA positive. Subjects who meet the following criteria may be enrolled: HBV-DNA <500 IU/mL measured within 28 days prior to study dosing, have received at least 4 weeks of standard antiviral therapy, and are willing to continue antiviral therapy throughout the study period.) Participants who are allergic to the test drug or any auxiliary materials. The vaccine was administered within 30 days before first dose or planned during treatment and up to 90 days after the last dose. Severe active infection within 2 weeks before first dose. Other factors that may increase study risk, interfere with results, or render the patient unsuitable per investigator judgment.
引自 ClinicalTrials.gov, NCT07408635, 参与标准,读取于 2026年11月10日。
这些信息从哪里来
登记记录
ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT07408635,读取于 2026年11月18日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。
疾病与医院
本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义
没有收录的内容
登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。